33.4 Analgesics for Acute Dental Pain

Analgesic Ladder for Acute Dental Pain

Dental pain is predominantly inflammatory, triggered by cellular membrane disruption, phospholipase $A_2$ activation, and the arachidonic acid cascade. The resulting generation of prostaglandins ($PGE_2, PGI_2$) sensitizes peripheral nociceptive A-delta and C fibres to inflammatory mediators such as bradykinin and histamine.

                          Arachidonic Acid Cascade
                                     │
                ┌────────────────────┴────────────────────┐
                ▼                                         ▼
     Cyclooxygenase-1 (COX-1)                  Cyclooxygenase-2 (COX-2)
   - Constitutive / Physiological             - Inducible / Inflammatory
   - Gastric mucosal protection (PGE2)       - Pain, fever, hyperalgesia
   - Renal blood flow autoregulation         - Endothelial prostacyclin (PGI2)
   - Platelet Thromboxane A2 (haemostasis)
                │                                         │
                └────────────────────┬────────────────────┘
                                     │
                       Inhibited by Non-Selective NSAIDs
                         (e.g., Ibuprofen, Naproxen)

1. Paracetamol (Acetaminophen)

• Mechanism of Action: Primarily acts as a central analgesic and antipyretic. It inhibits central nervous system prostaglandin synthesis (putative COX-3 or peroxidase catalytic site inhibition within neural environments where peroxide concentrations are low). It possesses negligible peripheral anti-inflammatory activity. Recent evidence also identifies active metabolite AM404, which acts on cannabinoid $CB_1$ receptors and stimulates descending serotonergic inhibitory pain pathways.
• Adult Dosing: 500 mg to 1000 mg every 4–6 hours as required, up to a strict maximum of 4000 mg (4 g) in 24 hours.
• Hepatotoxicity & Toxicological Mechanism:
  • In therapeutic doses, 85–90% of paracetamol is cleared via hepatic phase II glucuronidation and sulfation into benign metabolites. Only 5–10% is metabolized by cytochrome P450 (predominantly CYP2E1) into the highly reactive, electrophilic, hepatotoxic intermediate N-acetyl-p-benzoquinone imine (NAPQI).
  • Under normal conditions, NAPQI is instantly detoxified by conjugation with endogenous hepatic glutathione into non-toxic mercapturic acid conjugates excreted in urine.
  • In overdose ($>75-150\text{ mg/kg}$ or $>4-8\text{ g}$), the protective glucuronide and sulfate pathways become completely saturated. Excess drug is shunted to CYP2E1, generating massive amounts of NAPQI that deplete hepatic glutathione stores. Unconjugated NAPQI binds covalently to cysteinyl sulfhydryl groups on hepatocyte mitochondrial proteins, causing widespread acute centrilobular hepatic necrosis and fulminant liver failure.
  • Antidotal Therapy: Intravenous N-acetylcysteine (NAC) acts as a glutathione precursor and synthetic sulfhydryl donor, replenishing glutathione stores and directly conjugating NAPQI if administered within 8–12 hours of acute ingestion.

2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Mechanism of Action: Competitive, reversible inhibition of both cyclooxygenase isoforms: COX-1 (constitutive) and COX-2 (inducible). By halting prostaglandin $E_2$ synthesis at the peripheral site of tissue injury, NSAIDs directly suppress peripheral nociceptor sensitization, providing superior analgesia for inflammatory odontogenic conditions.
• Adult Dosing (Ibuprofen): 400 mg to 600 mg three to four times daily (tds/qds) taken with or after food, up to a maximum of 2400 mg (2.4 g) in 24 hours.
• High-Yield Clinical Contraindications & Risks:
  • Gastrointestinal Ulceration & Bleeding: Inhibition of COX-1 shuts down gastric mucosal prostaglandin ($PGE_2, PGI_2$) production, which normally promotes protective bicarbonate and mucus secretion and maintains mucosal blood flow. Concomitant use with systemic corticosteroids, SSRIs, or anticoagulants dramatically amplifies haemorrhage risk.
  • Renal Impairment & The "Triple Whammy": Renal prostaglandins maintain vasodilation of the afferent renal arteriole, preserving glomerular filtration rate (GFR). NSAID-induced prostaglandin inhibition causes unmitigated afferent arteriolar constriction. Co-prescribing NSAIDs with an ACE inhibitor (which dilates the efferent arteriole) and a Diuretic (which reduces plasma volume) precipitates severe acute tubular necrosis and acute renal failure (the classic "Triple Whammy").
  • Aspirin-Exacerbated Respiratory Disease (AERD) / NSAID-Sensitive Asthma: Up to 10–20% of adult asthmatics possess AERD. Cyclooxygenase blockade shunts arachidonic acid metabolism down the alternative 5-lipoxygenase (5-LOX) enzymatic pathway. This causes massive overproduction of cysteinyl leukotrienes ($LTC_4, LTD_4, LTE_4$), triggering life-threatening bronchoconstriction, mucosal oedema, and rhinorrhoea.
  • Cardiovascular Thrombotic Events (MHRA Guidance): Selective COX-2 inhibitors and high-dose ibuprofen ($\ge 2400\text{ mg/day}$) suppress vascular endothelial prostacyclin ($PGI_2$, an anti-thrombotic vasodilator) without inhibiting platelet thromboxane $A_2$ ($TXA_2$, a pro-thrombotic vasoconstrictor). This shifts the haemostatic balance toward thrombosis, increasing the risk of myocardial infarction and stroke. Contraindicated in established congestive heart failure (NYHA II–IV), ischaemic heart disease, and peripheral arterial disease.

3. Synergistic Multimodal Regimens vs. Opioids

                                  Pain Relief Comparison
  Regimen                                                    Number Needed to Treat (NNT)*
  ────────────────────────────────────────────────────────────────────────────────────────
  Ibuprofen 400 mg + Paracetamol 1000 mg (Combined)          ███ 1.5  (Exceptional)
  Ibuprofen 400 mg alone                                     ████ 2.4 (Good)
  Paracetamol 1000 mg alone                                  ██████ 3.6 (Moderate)
  Codeine 60 mg alone                                        █████████████ 16.7 (Poor)
  ────────────────────────────────────────────────────────────────────────────────────────
  *NNT: Lower values denote superior clinical efficacy (proportion of patients achieving >=50% pain relief).

• The Evidence-Based Dual Regimen: High-quality Cochrane systematic reviews establish that co-administering Paracetamol 1000 mg plus Ibuprofen 400 mg provides far greater pain relief (NNT ~1.5) than either drug alone, with longer duration and fewer adverse events. The mechanisms are complementary: peripheral prostaglandin suppression (ibuprofen) combined with central nociceptive attenuation (paracetamol).
• Opioids in Dentistry (Codeine, Dihydrocodeine, Tramadol):
  • Opioids act centrally on $\mu$-opioid receptors to alter pain perception, but have no peripheral anti-inflammatory action. They are ineffective against inflammatory dental pain when compared to NSAIDs.
  • Pharmacogenetic Trap: Codeine is an inactive prodrug that requires metabolic bioactivation to morphine via hepatic CYP2D6. In the UK population, approximately 7–10% of individuals are poor metabolisers who obtain zero analgesic relief from codeine, while 1–2% are ultra-rapid metabolisers who generate rapid, toxic concentrations of morphine, risking fatal respiratory depression.
  • Adverse effects include severe nausea, vomiting, dizziness, constipation, sedation, cognitive impairment, and rapid physiological dependence. Codeine and other opioids have no place as routine dental analgesics.

---